A Phase 2, Randomized, Open Label Trial of Lenalidomide/Dexamethasone With or Without Elotuzumab in Subjects With Previously Untreated Multiple Myeloma in Japan
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Elotuzumab (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 29 Nov 2017 According to a Bristol-Myers Squibb media release, data of the trial will be present at the 59th Annual Meeting & Exposition of the American Society of Hematology 2017.
- 17 Apr 2017 Planned End Date changed from 1 Sep 2018 to 31 Dec 2020.
- 07 Oct 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2017.